| Literature DB >> 27888630 |
Daniele Balasus1, Michael Way2, Caterina Fusilli3, Tommaso Mazza3, Marsha Y Morgan2, Melchiorre Cervello4, Lydia Giannitrapani1, Maurizio Soresi1, Rosalia Agliastro5, Manlio Vinciguerra2,6, Giuseppe Montalto1,4.
Abstract
Hepatocellular carcinoma (HCC) has one of the worst prognoses amongst all malignancies. It commonly arises in patients with established liver disease and the diagnosis often occurs at an advanced stage. Genetic variations, such as single nucleotide polymorphisms (SNPs), may alter disease risk and thus may have use as predictive markers of disease outcome. The aims of this study were (i) to assess the association of two SNPs, rs430397 in GRP78 and rs738409 in PNPLA3 with the risk of developing HCC in a Sicilian association cohort and, (ii) to use a machine learning technique to establish a predictive combinatorial phenotypic model for HCC including rs430397 and rs738409 genotypes and clinical and laboratory attributes. The controls comprised of 304 healthy subjects while the cases comprised of 170 HCC patients the majority of whom had hepatitis C (HCV)-related cirrhosis. Significant associations were identified between the risk of developing HCC and both rs430397 (p=0.0095) and rs738409 (p=0.0063). The association between rs738409 and HCC was significantly stronger in the HCV positive cases. In the best prediction model, represented graphically by a decision tree with an acceptable misclassification rate of 17.0%, the A/A and G/A genotypes of the rs430397 variant were fixed and combined with the three rs738409 genotypes; the attributes were age, sex and alcohol. These results demonstrate significant associations between both rs430397 and rs738409 and HCC development in a Sicilian cohort. The combinatorial predictive model developed to include these genetic variants may, if validated in independent cohorts, allow for earlier diagnosis of HCC.Entities:
Keywords: genetic variants; hepatitis C virus; hepatocellular carcinoma; risk factors; single nucleotide polymorphisms
Mesh:
Substances:
Year: 2016 PMID: 27888630 PMCID: PMC5349954 DOI: 10.18632/oncotarget.13558
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Characteristics of the healthy controls and HCC cases included in the genetic association study
| Variable | Controls (n=304) | HCC cases (n=170) |
|---|---|---|
| 56.6 ± 8.1 | 70.2 ± 8.0 | |
| Men | 214 (70.4) | 99 (58.2) |
| Women | 90 (29.6) | 71 (41.8) |
| HCV | 144 (84.7) | |
| Alcohol | 10 (5.9) | |
| Cryptogenic | 10 (5.9) | |
| HBV | 9 (5.3) | |
| Dysmetabolic syndrome | 1 (0.6) |
Data are mean ± 1SD or number (%)
Abbreviations: HCV- hepatitis C virus; HBV- hepatitis B virus.
Historical, clinical, laboratory, imaging and histological information used to diagnosis cirrhosis in the HCC cases
| Variables used to diagnose cirrhosis | Cases (n=170) |
|---|---|
| Affected/abnormal n (%) | |
| Variceal hemorrhage | 66 (38.8) |
| Ascites | 44 (25.9) |
| Hepatic encephalopathy | 10 (5.9) |
| Thrombocytopaenia* | 137 (80.6) |
| Prolonged prothrombin time* | 53 (31.2) |
| Hypoalbuminaemia* | 13 (7.6) |
| Hyperbilirubinaemia* | 11 (6.5) |
| Ultrasound | 163 (95.9) |
| CT-Scan | 8 (4.7) |
| Endoscopy | 5 (2.9) |
| 20 (11.8) |
* Laboratory cut-off values: platelet count: < 150 × 109/L, Prothrombin time > 40 sec, plasma albumin < 35 g/L, serum bilirubin > 1.2 mg/dl.
Laboratory, imaging and histological information used to diagnose HCC
| Variables used to diagnose cirrhosis | Cases (n=170) |
|---|---|
| Affected/abnormal n (%) | |
| Elevated serum alpha-fetoprotein* | 37 (21.8) |
| CT-Scan | 146 (85.9) |
| Ultrasound | 27 (15.9) |
| MRI-Scan | 27 (15.9) |
| 20 (11.8) |
* Laboratory cut-off values: serum alpha-fetoprotein > 400 ng/ml.
Allelic associations between the SNPs rs430397 and rs738409 in sicilian cases with HCC and healthy controls
| Gene (SNP) | Group | n | Minor Allele | Genotype Counts | MAF | Cases vs Controls | |||
|---|---|---|---|---|---|---|---|---|---|
| Significance p | OR (95% CI) | ||||||||
| AA | AG | GG | |||||||
| Cases | 170 | A | 1 | 46 | 123 | 0.141 | 0.016 | 1.65(1.09-2.50) | |
| Controls | 304 | 2 | 51 | 251 | 0.090 | ||||
| GG | CG | CC | |||||||
| Cases | 170 | G | 35 | 64 | 71 | 0.39 | 4.22×10-3 | 1.50 (1.14-1.98) | |
| Controls | 304 | 28 | 128 | 148 | 0.30 | ||||
Abbreviations: SNP – Single nucleotide polymorphism; n – number; MAF – Minor allele frequency; OR: Odds ratio; CI: Confidence Interval.
Associations between rs430397 and rs738409 genotypes in sicilian cases with HCC and healthy controls using different genetic models
| Gene (SNP) | Model | Entire cohort (n=474) | Entire cohort excluding non HCV-related cases (n=448) | ||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | ||||
| Allelic | 0.014 | 1.71 | 1.11-2.63 | 0.0348 | 1.64 | 1.04-2.58 | |
| Dominant | 0.0095 | 1.81 | 1.16-2.83 | 0.0190 | 1.76 | 1.10-2.82 | |
| Recessive | 0.93 | 0.89 | 0.08-9.93 | - | - | - | |
| Allelic | 0.0065 | 1.45 | 1.11-1.90 | 0.00363 | 1.52 | 1.15-2.02 | |
| Dominant | 0.15 | 1.32 | 0.91-1.93 | 0.127 | 1.37 | 0.92-2.04 | |
| Recessive | 0.0063 | 2.56 | 1.49-4.38 | 2.41×10-3 | 2.82 | 1.62-4.90 | |
Abbreviations: SNP – Single nucleotide polymorphism; OR: Odds ratio; CI: Confidence Interval.
Association between rs430397 and rs738409 and demographic, clinical and laboratory variables in the HCC cases
| Characteristics | rs430397 | rs738409 | ||||||
|---|---|---|---|---|---|---|---|---|
| A/A + G/A (n=47) | G/G (n=123) | C/C (n=71) | C/G (n=64) | G/G (n=35) | ||||
| Age (years): | ||||||||
| <71 | 21 (44.7%) | 59 (48%) | 35 (49.3%) | 31 (48.4%) | 14 (40%) | 0.942 | 0.4867 | |
| >=71 | 26 (55.3%) | 64 (52%) | 0.832 | 36 (50.7%) | 33 (51.6%) | 21 (60%) | ||
| Gender: | ||||||||
| M | 23 (48.9%) | 76 (61.8%) | 44 (62%) | 38 (59.4%) | 17 (48.6%) | 0.895 | 0.270 | |
| F | 24 (51.1%) | 47 (38.2%) | 0.178 | 27 (38%) | 26 (40.6%) | 18 (51.4%) | ||
| HCV: | ||||||||
| Yes | 39 (83%) | 105 (85.4%) | 59 (83.1%) | 53 (82.8%) | 32 (91.4%) | 0.853 | 0.389 | |
| No | 8 (17%) | 18 (14.6%) | 0.882 | 12 (16.9%) | 11 (17.2%) | 3 (8.6%) | ||
| HBV: | ||||||||
| Yes | 3 (6.4%) | 6 (4.9%) | 5 (7%) | 3 (4.7%) | 1 (2.9%) | 0.831 | 0.667 | |
| No | 44 (93.6%) | 117 (95.1%) | 0.993 | 66 (93%) | 61 (95.3%) | 34 (97.1%) | ||
| Alcohol: | ||||||||
| Yes | 3 (6.4%) | 7 (5.7%) | 4 (5.6%) | 6 (9.4%) | 0 (0%) | 0.617 | 0.374 | |
| No | 44 (27.5%) | 116 (94.3%) | 0.847 | 67 (94.4%) | 58 (90.6%) | 35 (100%) | ||
| Cirrhosis: | ||||||||
| Yes | 47 (100%) | 122 (99.2%) | 71 (100%) | 64 (100%) | 34 (97.1%) | 0.606 | 0.717 | |
| No | 0 (0%) | 1 (0.8%) | 0.616 | 0 (0%) | 0 (0%) | 1 (2.9%) | ||
| Cryptogenic: | ||||||||
| Yes | 4 (8.5%) | 6 (4.9%) | 4 (5.6%) | 4 (6.2%) | 2 (5.7%) | 0.831 | 0.667 | |
| No | 43 (91.5%) | 117 (95.1%) | 0.592 | 67 (94.4%) | 60 (93.7%) | 33 (94.3%) | ||
| Dysmetabolic: | ||||||||
| Yes | 0 (0%) | 1 (0.8%) | 0 (0%) | 1 (1.6%) | 0 (0%) | 0.958 | 7.00×10-3 | |
| No | 47 (100%) | 122 (99.2%) | 0.616 | 71 (100%) | 63 (98.4%) | 35(100%) | ||
| Ascites: | ||||||||
| Yes | 11 (23.4%) | 33 (26.8%) | 22 (31%) | 12 (18.8%) | 10 (28.6%) | 0.958 | 0.976 | |
| No | 36 (76.6%) | 90 (73.2%) | 0.795 | 49 (69%) | 52 (81.2%) | 25 (71.4%) | ||
| Variceal hemorrhage: | ||||||||
| Yes | 16 (34%) | 50 (40.7%) | 28 (39.4%) | 19 (29.7%) | 19 (54.3%) | 0.314 | 0.215 | |
| No | 31 (66%) | 73 (59.3%) | 0.539 | 43 (60.6%) | 45 (70.3%) | 16 (45.7%) | ||
| Hepatic encephalopathy: | ||||||||
| Yes | 1 (2.1%) | 9 (7.3%) | 6 (8.5%) | 2 (3.1%) | 2 (5.7%) | 0.345 | 0.912 | |
| No | 46 (97.9%) | 114 (92.7%) | 0.357 | 65 (91.5%) | 62 (96.9%) | 33 (94.3%) | ||
| Thrombocytopaenia: | ||||||||
| Yes | 42 (89.4%) | 95 (77.2%) | 55 (77.5%) | 52 (81.5%) | 30 (85.7%) | 0.742 | 0.458 | |
| No | 5 (10.6%) | 28 (22.8%) | 0.116 | 16 (22.5%) | 12 (18.8%) | 5 (14.3%) | ||
| Prolonged prothrombin time | ||||||||
| Yes | 16 (34%) | 37 (30.1%) | 23 (32.4%) | 20 (31.2%) | 10 (28.6%) | 0.966 | 0.860 | |
| No | 31 (66%) | 86 (69.9%) | 0.754 | 48 (67.6%) | 44 (68.7%) | 25 (71.4%) | ||
| Hyperbilirubinaemia | ||||||||
| Yes | 5 (10.6%) | 6 (4.9%) | 3 (4.2%) | 5 (7.8%) | 3 (8.6%) | 0.606 | 0.643 | |
| No | 42 (89.4%) | 117 (95.1%) | 0.309 | 68 (95.8%) | 59 (92.2%) | 32 (91.4%) | ||
| Hypoalbuminaemia | ||||||||
| Yes | 4 (8.4%) | 9 (7.3%) | 4 (5.6%) | 7 (10.9%) | 2 (5.7%) | 0.418 | 0.667 | |
| No | 43 (91.5%) | 114 (92.7%) | 0.952 | 67 (94.4%) | 57 (89.1%) | 33 (94.3%) | ||
| Raised serum alphafetoprotein | ||||||||
| Yes | 8 (17%) | 29 (23.6%) | 0.472 | 16 (22.5%) | 16 (25%) | 5 (14.3%) | 0.894 | 0.458 |
| No | 39 (83%) | 94 (76.4%) | 55 (77.5%) | 48 (75%) | 30 (85.7%) | |||
Figure 1Decision tree based on the genotypes of both PNPLA3 and GRP78 SNPs
In this analysis the included discriminating attributes were: age, sex, HCV status, ascites, variceal haemorrhage, prolonged prothrombin time (PTT), elevated serum alpha-fetoprotein (AFP). The first genotype refers to the rs430397 variant and the second, separated by “-”, refers to the rs738409 variant. The ratio of the genotypes accurately classified over those wrongly classified is provided for each genotype in brackets.
Figure 2Decision tree developed fixing the rs430397 G/G genotype
In this analysis, the most discriminating attributes were: age, sex, HBV, steatosis, ascites, variceal haemorrhage, thrombocytopenia, prolonged prothrombin time (PTT), elevated serum alpha-fetoprotein (AFP). The genotype in the box refers to rs738409. The ratio of the genotypes accurately classified over those wrongly classified is provided for each genotype in brackets.
Figure 3Decision tree developed fixing the rs430397 A/A and G/A genotypes
This analysis selected the age, sex and alcohol variables. The genotype in the box refers to the rs738409 SNP. The ratio of the genotypes accurately classified over those wrongly classified is provided for each genotype in brackets.